Please assess the completion status of the following clinical trial:

Trial Title: Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion~* Patients with the following diagnoses are eligible for this study: Advanced myeloid malignancy with a disease status of more than second remission, induction failure, or relapse; Chronic myeloid leukemia in blast crisis; Myelodysplasia, specifically refractory anemia with excess blasts (RAEB)~* All candidates for this study must have a HLA (-A, -B, -C, -DR) identical sibling who is willing to donate bone marrow or primed blood stem cells or a 10/10 allele-matched unrelated donor or minor mismatches as per BMT SOP that allows Tacrolimus and Sirolimus to be given for GVH prophylaxis; all ABO blood group combinations of the donor/recipient are acceptable since even major ABO compatibilities can be dealt with by various techniques (red cell exchange or plasma exchange)~* Prior therapy with VP-16, busulfan, hydrea and gleevec are allowed~* A cardiac evaluation with electrocardiogram and MUGA or echocardiogram is required for all patients; patients must have an ejection fracture of greater than or equal to 50%~* Patients must have a serum creatinine of less than or equal to 1.2 or creatinine clearance \> 80 ml/min~* A bilirubin of less than or equal to 1.5; patients should also have an SGOT and SGPT less than 5 times the upper limit of normal~* Pulmonary function tests including DLCO will be performed; FEV1 and DLCO should be greater than 50% of predicted normal value~* Time from the end of last induction or reinduction attempt should be greater than or equal to 21 days~* A signed (IRB approved) informed consent document is required; the patient, donor family member, and transplant team (physician, nurse, and social worker) meet together at least once prior to starting the transplant procedure to review all pertinent risk/benefit information as part of the consenting process; alternative treatment modalities are also discussed at this meeting~Exclusion~* Prior radiation therapy/exposure that prevents patient from receiving IMRT (Determination will be made by the Radiation Oncologist)~* Patients who have previously undergone a blood/marrow transplant and now have relapsed disease~* Patients with a psychological or medical condition that the treating physician deems unacceptable to proceed to allogeneic bone marrow transplant~* Pregnancy~* EKG showing ischemic changes or abnormal rhythm and echocardiogram showing ejection fraction \< 50 % or abnormal wall motion

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Arm I: 1200cGy (Type: EXPERIMENTAL): 1200cGy = 150cGy x 8 doses: Patients receive busulfan IV once daily over 2 hours on days -15 and -13 and then every 6 hours on days -12 to -9. Patients also receive etoposide IV on day -3. Patients undergo image-guided intensity-modulated radiation therapy using helical tomotherapy on days -8 to -5.~TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation or bone marrow transplantation on day 0.~GRAFT-VS-HOST DISEASE (GVHD) PROPHYLAXIS: Patients receive GVHD prophylaxis that excludes methotrexate.
- Arm II: 1350cGy (Type: EXPERIMENTAL): 1350cGy = 150cGy x 9 doses: Patients receive busulfan IV once daily over 2 hours on days -15 and -13 and then every 6 hours on days -12 to -9. Patients also receive etoposide IV on day -3. Patients undergo image-guided intensity-modulated radiation therapy using helical tomotherapy on days -8 to -5.

Based on this trial design, predict the completion outcome and termination type (if applicable).